Photo: Depositphotos
Apr 17, 2025, 06:24
Goutham Sunny: Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib
Goutham Sunny, Resident Doctor at The Gujarat Cancer and Research Institute, posted on X:
“PALMARES-2 real world data shows Abemaciclib>Ribociclib>Palbociclib.
This data will definitely help in choosing between the CDK4/6i.”
“Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR+/HER2- BC patients: results from the multicenter PALMARES-2 study.”
Authors: L. Provenzano, M.V. Dieci, G. Curigliano, M. Giuliano, A. Botticelli, M. Lambertini, G. Rizzo, R. Pedersini, M. Sirico, N. La Verde, A. Gennari, A. Zambelli, A. Toss, M. Piras, M. Giordano, B. Tagliaferri, D. Generali, D. Sartori, D. Miliziano, A. Menichetti, F. Ligorio, C. Zurlo, G. Griguolo, P.P. Berton Giachetti, V. Faso, C. Corti, E. Chiappe, S. Scagnoli, S. Pisegna, C. Capasso, C. De Angelis, G. Arpino, C. Criscitiello, V. Guarneri, G. Pruneri, L. Mariani, C. Vernieri
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 10, 2025, 23:57